Compare GSK plc (GSK) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Remitly Global Inc — how do they compare? GSK plc trades at $50.28 (market cap $102.60B), while Remitly Global Inc trades at $23.85 (market cap $4.97B). The key difference: GSK plc is far larger — about 20.6× Remitly Global Inc's market cap, and GSK plc pays a 3.57% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| GSK | RELY | |
|---|---|---|
Market Cap | $102.60B | $4.97B |
Sector | Health | Technology |
52-Week High | $61.18 | $25.93 |
52-Week Low | $38.22 | $12.20 |
Enterprise Value | $123.04B | $4.33B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
RELY trades at $23.14, down 5.24% over 24 hours, but maintains a bullish technical signal with key support at $22. The company reported strong Q2 2026 results, beating EPS estimates with $0.93 actual versus $0.12 expected, and revenue growth of 20% year-over-year. Profitability has improved significantly, with net income margin reaching 16.85% in 2026 from negative margins in prior years. Recent news highlights expansion into new financial services like the Global Card and regulatory approvals in the UAE.
The outlook is positive, driven by robust earnings growth, market share gains, and strategic initiatives beyond core remittances. Risks include competitive pressures and execution of new business lines. Analyst consensus is strongly bullish with a $31 price target, suggesting substantial upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
